Comparison of antisense oligonucleotide drug delivery systems

Journal of Controlled Release

Volumn 100, Issue 3, 2004, Pages 411-423

  Weyermann, Jörg ^a   Lochmann, Dirk ^a   Zimmer, Andreas ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Antisense oligonucleotide; Drug delivery systems; Liposomes; Nanoparticles; NMDA receptor; Polyoma; Protamine; Proticles; VP1

Indexed keywords

CONFOCAL LASER SCAN MICROSCOPY (CLSM); MICROPLATE FLUORESCENCE QUANTIFICATION; OLIGONUCLEOTIDE DRUG DELIVERY SYSTEM;

AMINES; DNA; FLUORESCENCE; GENES; PROTEINS; REDUCTION; TOXICITY; VIRUSES;

DRUG PRODUCTS;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ACRYLIC ACID; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; LIPOFECTIN; LIPOSOME; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NANOPARTICLE; PROTAMINE; PROTEIN VP1;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL MEMBRANE TRANSPORT; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DNA TRANSFECTION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; FIBROBLAST; FLUORESCENCE; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE CHARGE; TOXICITY TESTING; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; CYANOACRYLATES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ELECTROCHEMISTRY; FIBROBLASTS; GENE THERAPY; IMAGE PROCESSING, COMPUTER-ASSISTED; MICE; MICROSPHERES; OLIGONUCLEOTIDES, ANTISENSE; PARTICLE SIZE; PROTAMINES; SURFACE PROPERTIES; VEHICLES;

EID: 9644260518     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.08.027     Document Type: Article

References (49)

1. M.L. Stephenson, and P.C. Zamecnik Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide Proc. Natl. Acad. Sci. U. S. A. 75 1978 285 288
2. P.C. Zamecnik, and M.L. Stephenson Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide Proc. Natl. Acad. Sci. U. S. A. 75 1978 280 284
3. I. Lebedeva, and C.A. Stein Antisense oligonucleotides: promise and reality Annu. Rev. Pharmacol. Toxicol. 41 2001 403 419
4. A. Harada, H. Togawa, and K. Kataoka Physicochemical properties and nuclease resistance of antisense-oligodeoxynucleotides entrapped in the core of polyion complex micelles composed of poly(ethylene glycol)-poly(l-lysine) block copolymers Eur. J. Pharm. Sci. 13 2001 35 42
5. A.A. Levin A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides Biochim. Biophys. Acta 1489 1999 69 84
6. C.A. Stein Phosphorothioate antisense oligodeoxynucleotides: questions of specificity Trends Biotechnol. 14 1996 147 149
7. W.M. Bertling, M. Gareis, V. Paspaleeva, A. Zimmer, J. Kreuter, E. Nurnberg, and P. Harrer Use of liposomes, viral capsids, and nanoparticles as DNA carriers Biotechnol. Appl. Biochem. 13 1991 390 405
8. A.M. Gewirtz, D.L. Sokol, and M.Z. Ratajczak Nucleic acid therapeutics: state of the art and future prospects Blood 92 1998 712 736
9. H.P. Zobel, M. Junghans, V. Maienschein, D. Werner, M. Gilbert, H. Zimmermann, C. Noe, J. Kreuter, and A. Zimmer Enhanced antisense efficacy of oligonucleotides adsorbed to monomethylaminoethylmethacrylate methylmethacrylate copolymer nanoparticles Eur. J. Pharm. Biopharm. 49 2000 203 210
10. H. Braun, K. Boller, J. Lower, W.M. Bertling, and A. Zimmer Oligonucleotide and plasmid DNA packaging into polyoma VP1 virus-like particles expressed in Escherichia coli Biotechnol. Appl. Biochem. 29 Pt 1 1999 31 43
11. S. Henke, A. Rohmann, W.M. Bertling, T. Dingermann, and A. Zimmer Enhanced in vitro oligonucleotide and plasmid DNA transport by VP1 virus-like particles Pharm. Res. 17 2000 1062 1070
12. S.M. Barr, K. Keck, and H.V. Aposhian Cell-free assembly of a polyoma-like particle from empty capside and DNA Virology 96 1979 656 659
13. P.L. Felgner, T.R. Gadek, M. Holm, R. Roman, H.W. Chan, M. Wenz, J.P. Northrop, G.M. Ringold, and M. Danielsen Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure Proc. Natl. Acad. Sci. U. S. A. 84 1987 7413 7417
14. A. Quattrone, L. Papucci, M. Morganti, M. Coronnello, E. Mini, T. Mazzei, F.P. Colonna, A. Garbesi, and S. Capaccioli Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance Oncol. Res. 6 1994 311 320
15. J. Bertram, M. Killian, W. Brysch, K.H. Schlingensiepen, and M. Kneba Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides Biochem. Biophys. Res. Commun. 200 1994 661 667
16. O. Zelphati, and F.C. Szoka Jr. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids Pharm. Res. 13 1996 1367 1372
17. O. Zelphati, L.S. Uyechi, L.G. Barron, and F.C. Szoka Jr. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells Biochim. Biophys. Acta 1390 1998 119 133
18. S.T. Crooke Delivery of oligonucleotides and polynucleotides J. Drug Target. 3 1995 185 190
19. S. Douglas, L. Illum, and S. Davis Poly(butyl 2-cyanoacrylate) nanoparticles with differing surface charges J. Control. Release 3 1986 15 23
20. S. Pirker, J. Kruse, C.R. Noe, K. Langer, A. Zimmer, and J. Kreuter Characterization of polybutylcyanoacrylate nanoparticles: Part II. determination of polymer content by NMR-analysis Int. J. Pharm. 128 1995 189 195
21. H.P. Zobel, J. Kreuter, D. Werner, C.R. Noe, G. Kumel, and A. Zimmer Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides Antisense Nucleic Acid Drug Dev. 7 1997 483 493
22. M. Junghans, J. Kreuter, and A. Zimmer Antisense delivery using protamine-oligonucleotide particles Nucleic Acids Res. 28 2000 E45
23. M. Junghans, J. Kreuter, and A. Zimmer Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles Biochim. Biophys. Acta 1544 2001 177 188
24. D. Lochmann, V. Vogel, J. Weyermann, N. Dinauer, H. Briesen von, J. Kreuter, D. Schubert, and A. Zimmer Physicochemical characterisation of protamine-phosphorothioate nanoparticles J. Microencapsul 2004 (in press)
25. N. Dinauer, D. Lochmann, I. Demirhan, A. Zimmer, A. Chandra, J. Kreuter, and H. Briesen von Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transfection J. Control. Release 96 2004 497 507
26. A. Arnedo, J.M. Irache, M. Merodio, and M.S. Espuelas Millan Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide J. Control. Release 94 2004 217 227
27. F.E. Smith Tetrazolium salt Science 113 1951 751 754
28. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
29. R.D. Steinmetz, E. Fava, P. Nicotera, and D. Steinhilber A simple cell line based in vitro test system for N-methyl-d-aspartate (NMDA) receptor ligands J. Neurosci. Methods 113 2002 99 110
30. R.S. Geary, R.Z. Yu, and A.A. Levin Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides Curr. Opin. Investig. Drugs 2 2001 562 573
31. P.L. Nicklin, D. Bayley, J. Giddings, S.J. Craig, L.L. Cummins, J.G. Hastewell, and J.A. Phillips Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes Pharm. Res. 15 1998 583 591
32. A.K. Pannier, V. Arora, P.L. Iversen, and R.M. Brand Transdermal delivery of phosphorodiamidate morpholino oligomers across hairless mouse skin Int. J. Pharm. 275 2004 217 226
33. P.J. White, L.M. Atley, and C.J. Wraight Antisense oligonucleotide treatments for psoriasis Expert Opin. Biol. Ther. 4 2004 75 81
34. A.A. Raoof, P. Chiu, Z. Ramtoola, I.K. Cumming, C. Teng, S.P. Weinbach, G.E. Hardee, A.A. Levin, and R.S. Geary Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate J. Pharm. Sci. 93 2004 1431 1439
35. B. Le Bourdelles, K.A. Wafford, J.A. Kemp, G. Marshall, C. Bain, A.S. Wilcox, J.M. Sikela, and P.J. Whiting Cloning, functional coexpression, and pharmacological characterisation of human cDNAs encoding NMDA receptor NR1 and NR2A subunits J. Neurochem. 62 1994 2091 2098
36. G. Barratt Characterization of colloidal drug carrier systems with zeta potential measurements Pharmaceutical Technology Europe 1999 25 32
37. R. Finsy, and N. De Jaeger Particle sizing by photon correlation spectroscopy: Part II. Average values Part. Part. Syst. Charact. 8 1991 187 193
38. R. Finsy, N. De Jaeger, R. Sneyers, and E. Gelade Particle sizing by photon correlation spectroscopy: Part III. Mono and bimodal distribution and data analysis Part. Part. Syst. Charact. 9 1992 125 137
39. R. Finsy, L. Deriemaeker, N. De Jaeger, R. Sneyers, J. Vanderdeelen, P. Van der Meeren, H. Demeyere, J. Stone-Masui, A. Haestier, J. Clauwaert, W. De Wispelaere, P. Gillioen, S. Steyfkens, and E. Gelade Particle sizing by photon correlation spectroscopy: Part IV. Resolution of bimodal and comparison with other particles sizing methods Part. Part. Syst. Charact. 10 1993 118 128
40. B.J. Berne, and R. Pecora Dynamic Light Scattering-With Applications to Chemistry, Biology, and Physics vol. 2 2000 Dover Publications Mineola, NY
41. R. Pecora Dynamic light scattering measurement of nanometer particles in liquids J. Nanopart. Res. 2 2000 123 131
42. D.E. Koppel Analysis of macromolecular polydispersity in intensity correlation spectroscopy J. Chem. Phys. 57 1972 4814 4820
43. D. Lochmann, J. Weyermann, C. Georgens, R. Prassl, and A. Zimmer Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system: Part 1. Physicocemical characterisation Eur. J. Pharm. Biopharm. 2004 (in press)
44. V. Vogel, D. Lochmann, J. Weyermann, G. Mayer, C. Tziatios, J.A. van den Broek, W. Haase, D. Wouters, U.S. Schubert, J. Kreuter, A. Zimmer, and D. Schubert Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties and intracellular processing J. Control. Release 2004 (submitted)
45. G.R. Griffith, S.J. Marriott, D.A. Rintoul, and R.A. Consigli Early events in polyomavirus infection: fusion of monopinocytotic vesicles containing virions with mouse kidney cell nuclei Virus Res. 10 1988 41 51
46. C.N. Cole B.N. Fields D.M. Knipe P.M. Howley Fundamantal Virology 1996 Lippincott-Raven Philadelphia
47. V. Lenaerts, P. Couvreur, D. Christiaens-Leyh, E. Joiris, M. Roland, B. Rollman, and P. Speiser Degradation of poly (isobutyl cyanoacrylate) nanoparticles Biomaterials 5 1984 65 68
48. S. Prabha, W.Z. Zhou, J. Panyam, and V. Labhasetwar Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles Int. J. Pharm. 244 2002 105 115
49. I. Lebedeva, L. Benimetskaya, C.A. Stein, and M. Vilenchik Cellular delivery of antisense oligonucleotides Eur. J. Pharm. Biopharm. 50 2000 101 119